Large retroperitoneal lymph node (RPLN) is associated with venous thromboembolism (VTE) in patients with disseminated germ cell tumors (GCTs), providing better accuracy than high-risk Khorana score in this group, according to a recent study published in the Journal of Clinical Oncology.
Amirrtha Srikanthan, MD, of the Princess Margaret Cancer Centre in Toronto and fellow researchers looked at a training cohort of 216 patients with disseminated GCT who were receiving first-line chemotherapy from January 2000 to December 2010, with large RPLN defined as more than 5 centimeters in diameter.
Comparing predictive models using large RPLN with high-risk Khorana score in order to determine risk of VTE, the researchers found that the former method showed higher discriminatory accuracy, with further validation in a London cohort.
Twenty-one patients developed VTE during chemotherapy, and it was associated with large RPLN, high-risk Khorana score, intermediate- to poor-risk disease, and hospitalization.
“Prophylactic anticoagulation may be considered in high-risk patients,” the authors concluded. “Results should be validated in larger, prospective studies.”
RPLN is associated with VTE in patients with disseminated germ cell tumors.
The researchers hypothesized that there was an association between large RPLN and chemotherapy-associated VTE risk. Large RPLN is associated with VTE in patients with disseminated GCT and provides higher discriminatory accuracy than high-risk Khorana score.